Kymera Therapeutics (KYMR) Stock Research

Thursday

Kymera Therapeutics price target raised by $16 at Morgan Stanley, here's why

KYMR

Aug 6, 12:13 PM

Kymera Therapeutics price target raised by $15 at Citi, here's why

KYMR

Aug 6, 6:16 AM

Kymera Therapeutics price target raised by $6 at Barclays

KYMR

Aug 6, 5:34 AM

Wednesday

Kymera Therapeutics reports Q2 EPS (62c), consensus (74c)

KYMR

Aug 5, 7:44 AM

Over a week ago

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls

+11

Jul 30, 9:38 AM

Kymera Therapeutics initiated with neutral view at Deutsche Bank, here's why

KYMR

Jul 30, 4:19 AM

Kymera Therapeutics price target raised by $10 at Guggenheim, here's why

KYMR

Jul 28, 6:38 AM

Kymera Therapeutics CMO Jared Gollob to retire, Terence Rooney to succeed

KYMR

Jul 27, 4:02 PM

Kymera Therapeutics price target raised by $20 at Mizuho, here's why

KYMR

Jul 16, 6:48 AM

American Express, Biogen upgraded: Wall Street's top analyst calls

+12

Jul 13, 9:41 AM

Kymera Therapeutics just downgraded at RBC Capital, here's why

KYMR

Jul 13, 6:34 AM

Kymera Therapeutics price target raised by $15 at BofA, here's why

KYMR

Jun 30, 7:52 AM

Kymera Therapeutics price target raised by $38 at B. Riley, here's why

KYMR

Jun 29, 8:32 AM

Kymera Therapeutics price target raised by $20 at Truist, here's why

KYMR

Jun 29, 7:22 AM

Kymera Therapeutics price target raised by $23 at Canaccord, here's why

KYMR

Jun 26, 7:55 AM

What You Missed On Wall Street On Thursday

+23

Jun 25, 4:11 PM

Midday Fly By: Micron reports blowout Q3, Apple boosts MacBook prices

+24

Jun 25, 12:05 PM

Kymera Therapeutics rises 18.6%

KYMR

Jun 25, 10:00 AM

Kymera Therapeutics completes enrollment in BROADEN2 trial

KYMR

Jun 25, 7:15 AM

Kymera Therapeutics appoints Felix Baker as chairman

KYMR

Jun 24, 4:05 PM

Canaccord sees potential Apogee buyout as 'huge win' for sector

Jun 22, 6:45 AM

Kymera Therapeutics participates in a conference call with JPMorgan

KYMR

Jun 17, 1:21 PM

Kymera Therapeutics presents preclinical lupus data for KT-579

KYMR

Jun 8, 9:06 AM

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls

+13

May 6, 9:38 AM

Pioneering TPD Platform: Kymera's proprietary PLAT.Rx® platform provides a systematic and efficient engine for the discovery and development of novel targeted protein degraders, offering a significant technological edge in the field.

First-in-Class Clinical Pipeline: The company has advanced multiple first-in-class degraders into clinical development, notably KT-333 (STAT3 degrader) and KT-6121 (MEK degrader), addressing previously undruggable or challenging targets with high commercial potential.

Broad Therapeutic Reach: Kymera's pipeline spans multiple high-value therapeutic areas, including oncology and immunology, diversifying its risk and expanding the potential market opportunities for its degrader programs.

Clinical Trial Failure and Delays: Kymera's drug candidates may not demonstrate sufficient efficacy or safety in clinical trials, leading to program termination or significant delays in development.

Regulatory Approval Uncertainty: Even with successful clinical trial data, Kymera's drug candidates may not receive necessary regulatory approvals from health authorities, preventing commercialization.

Intense Market Competition: Kymera faces significant competition from other pharmaceutical and biotechnology companies developing treatments for similar indications, which could impact market share and profitability.

Charts

Clinical Trial Failure and Delays: Kymera's drug candidates may not demonstrate sufficient efficacy or safety in clinical trials, leading to program termination or significant delays in development.